Business Wire

Cell Therapy Tools for Cartilage Repair From Osteoarthritic Knee Joint of Elderly

18.6.2020 08:34:00 EEST | Business Wire | Press release

Share

A break through feat of growing pluripotency expressing cells from osteoarthritis (OA) affected cartilage tissue of knee joints of elderly has been reported by orthopedicians and cell culture experts led by Dr Shojiro Katoh, President, Edogawa Hospital. OA affects, knee joints of millions globally and those with severe disease, undergo Total Knee Arthroplasty (TKA), in which damaged cartilage is replaced with artificial knee prosthesis. Dr Katoh, during TKA surgery, took portions of the damaged tissue, which otherwise is discarded, isolated chondrocyte cells in tissue engineering lab, and could culture them as fully reorganized healthy cartilage tissue, expressing biomarkers relevant to pluripotency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005880/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

"Pluripotency expressing cells grown from osteoarthritis affected knee joint, open doors to a spectrum of novel solutions to address cartilage damage," says Dr. Shojiro Katoh, President, Edogawa Hospital, Tokyo, Japan. (Photo: Business Wire)

Cartilage of the knee joint acts as a cushion between bones of the thigh and leg and absorbs the body weight. When cartilage is damaged due to sports injury, trauma or wear and tear, it causes joint pain and disability. In early stage of the disease, Autologous Chondrocyte Implantation (ACI) or Matrix Assisted Chondrocyte Implantation (MACI) are practiced. Such cell therapies use patient’s own cartilage cells, harvested from healthy, non-weight bearing area, grown in lab, and transplanted to replace the damaged tissue, to restore functionality.

"This could probably be the world’s first report of Osteoarthritis tissue, yielding cells expressing pluripotency markers," said Dr. Katoh, citing their publication in Regenerative Therapy Journal (https://www.sciencedirect.com/science/article/pii/S2352320420300274), also presented in the 19th Japanese society for regenerative medicine meeting. "Our technique may help utilize OA affected cartilage, discarded as biomedical waste, as a source of tools of cell therapies viz., cells, cell secreted growth factors, and exosomes to repair cartilage defects in regenerative medicine," he added.

Edogawa hospital, located in eastern Tokyo, has many senior citizens. "Contrary to the age-old belief that Wisdom is the strength of elders, this research finding has made me humble, to learn about nature’s hidden strength in their physical intricacies too, fueling our enthusiasm," said Dr Katoh adding a philosophical humility to his accomplishment. His Edogawa Evolutionary Lab of Science (EELS), having confirmed hyaline phenotype is now evaluating miRNA-140 and Hyaluronan expression of chondrocytes.

This technology has a potential to solve cartilage damage of approximately 12 million people annually worldwide, according to JBM Inc, and GN Corporation, co-applicants to a patent and research partners to EELS.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Samuel JK Abraham
GN Corporation
info@gncorporation.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wolters Kluwer Named Top Vendor Law Firm SaaS Solution Provider in the DACH Region for 202720.7.2026 10:00:00 EEST | Press release

Wolters Kluwer’s Legal & Regulatory has been recognized as a top vendor for Law Firm SaaS Solutions in the DACH region for 2027, according to the latest Vendor Selection Matrix™ by Research in Action. Kleos, the company's cloud-native legal practice management platform, achieved a shared first-place position in the ranking and received the highest scores for customer satisfaction, value for money and customer recommendation among surveyed law firms in Germany, Austria and Switzerland. The recognition builds on the platform's earlier pan-European leadership position and reinforces Kleos' standing as one of Europe's leading legal practice management solutions. "We are proud to be recognized as a leading provider of Law Firm SaaS Solutions in the DACH region,” said Sergio Liscia, Vice President Legal Software at Wolters Kluwer. “What makes this recognition particularly meaningful is that it reflects the experience of legal professionals themselves. Achieving the highest ratings for custom

IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 09:00:00 EEST | Press release

IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260719172592/en/ IQM's whitepaper on hybrid quantum optimization for railway scheduling, developed with Deutsche Bahn. Using a real operational dataset from Deutsche Bahn, a schedule of 190 trips across five German cities translating into roughly 98,500 possible cycles, the two organizations developed and tested a hybrid quantum-classical algorithm designed for enterprise-scale optimization problems. As detailed in a published whitepaper here, the IQM team applied the Quantum Approximate Optimization Algorithm (QAOA) in manageable stages, with the quantum component solving smaller subproblems within a classic

Galderma Launches Alastin ® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent launches in China and Australia and underscores Galderma’s continued investment in JPAC, a region characterized by advanced skincare practices and rapid growth in injectable aesthetics.1,2 This is increasing demand for integrated skincare solutions that support skin readiness, recovery and long-term quality.3,4,5 Alastin addresses this need through its range of peri-procedural support and daily skincare products that amplify the skin’s natural regenerative abilities, supporting recovery and enhances visible outcomes of in-demand aesthetic procedures such as energy-based device

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 20:10:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic cancer and colorectal cancer, our TGFβR2×PD-1 bispecific antibody in microsatellite stable colorectal cancer and our CDK2 inhibitor in recurrent epithelial ovarian cancer – investigational approaches that reflect our focus on areas where there is significant need for novel therapies." Details on key data presentations at ESMO include: Rapid Oral Presentations INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Mono

STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 15:24:00 EEST | Press release

STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye